TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Notice of FY results and Presentation
via Investor Meet Company
Alderley Park, 20 May 2024
- TheraCryf plc (AIM: TCF), formerly Evgen Pharma
plc, the clinical stage drug development company focussing on
oncology and neuropsychiatry, announces that the
Company's full year financial results for the year to 31 March 2024
will be released on Tuesday 28 May 2024.
The results will be available via the London
Stock Exchange's Regulatory News Service (RNS) and on the Investor
Relations section of the Company's website: www.theracryf.com/investors.
Huw Jones, CEO, and Toni Hänninen, CFO will
provide a live presentation via the Investor Meet Company platform
at 3pm on Tuesday 28 May 2024.
The presentation is open to all existing and
potential shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard up until 27 May 2024, 09:00
BST, or at any time during the live presentation. Investors who
already follow TheraCryf plc on the Investor Meet Company platform
will automatically be invited.
Investors can sign up to Investor Meet Company
HERE.
-
Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
theracryf@Instinctif.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications such as neurodevelopmental disorders, glioblastoma*,
addiction, anxiety and narcolepsy* [*orphan indications]. Its
strategy is to generate compelling data sets to proof of concept
and/or later phase II to partner its clinical programmes with
mid-size to large pharma. As well as a number of industry
partnerships with companies, including Stalicla, in
neurodevelopment disorders and has sourced programmes from
companies such as Takeda and Shire, the Company has worked with and
has ongoing collaborations with major universities, hospitals and
government organisations such as the University of Manchester,
Sapienza (Università di Roma), Kings College London and University
of Connecticut.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com